Cookie policy notice

By continuing to use this site you agree to our cookies policy below:
Since 26 May 2011, the law now states that cookies on websites can ony be used with your specific consent. Cookies allow us to ensure that you enjoy the best browsing experience.

This site is intended for health professionals only

At the heart of general practice since 1960

NICE recommends new bisphosphonates role

The National Institute for Clinical Excellence is set to recommend the use of bisphos- phonates to treat a million post-menopausal women with severe osteoporosis.

A technology appraisal consultation document released by NICE recommends bisphosphonates (alendronate, etidronate and risedronate) in all post-menopausal women aged 65 and older who have had a fragility fracture, even without a DEXA scan.

Post-menopausal women under 65 would be eligible for the treatment provided a DEXA scan showed they had a T-score below -3.2 SD, or below -2.5 SD and a history of maternal hip fracture or long-term use of systemic steroids.

The extra cost to the NHS in England and Wales is estimated to be £75 million a year.

The guidance warns that before bisphosphonates are prescribed it should be established that the woman has adequate levels of calcium and vitamin D. The advice is in line with the national service framework for older people.

Bisphosphonates are not recommended for any woman who does not have a fragility fracture and raloxifene (Evista) is not recommended for treating osteoporosis in any post-menopausal women.

Teriparatide (Forsteo), an expensive new drug that promotes bone growth, is only recommended for very severe cases.

Rate this article 

Click to rate

  • 1 star out of 5
  • 2 stars out of 5
  • 3 stars out of 5
  • 4 stars out of 5
  • 5 stars out of 5

0 out of 5 stars

Have your say